Lördag 21 Mars | 16:17:16 Europe / Stockholm

Svenska | English

Oculis Holding

Kalender

	Est. tid*
2027-11-05	22:05	Kvartalsrapport 2027-Q3
2027-08-12	22:05	Kvartalsrapport 2027-Q2
2027-05-06	22:05	Kvartalsrapport 2027-Q1
2027-03-02	N/A	Bokslutskommuniké 2026
2026-11-05	22:05	Kvartalsrapport 2026-Q3
2026-08-06	22:05	Kvartalsrapport 2026-Q2
2026-05-07	22:05	Kvartalsrapport 2026-Q1
2026-03-03	-	Bokslutskommuniké 2025
2025-11-10	-	Kvartalsrapport 2025-Q3
2025-08-21	-	Kvartalsrapport 2025-Q2
2025-05-08	-	Kvartalsrapport 2025-Q1

Beskrivning

Land	Schweiz
Lista	Mid Cap Iceland
Sektor	Hälsovård
Industri	Bioteknik

Oculis Holding är specialiserade inom bioteknik. Bolaget bedriver forskning och utveckling inom topikala behandlingar för ögonsjukdomar. Exempel på specialistområden inkluderar diabetiskt makulaödem, bahandlingar för torra ögon och akut optisk neurit. Störst verksamhet återfinns inom Europa, där forskning bedrivs i egen regi men även via samarbetspartners. Bolaget har sitt huvudkontor i Zug, Schweiz.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-03-16 10:00:00 Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting 3250,00 ISK | -2,55% | 12,3 MISK

2026-03-16 08:24:05 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3250,00 ISK | -2,55% | 12,3 MISK

2026-03-13 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-03-11 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3330,00 ISK | -4,58% | 32,6 MISK

2026-03-06 22:01:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-03-05 10:00:00 Oculis to Participate in Upcoming Investor Conferences 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-05 10:00:00 Oculis Publishes 2025 Consolidated Financial Statements 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-05 10:00:00 Oculis to Participate in Upcoming Investor Conferences 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-04 22:15:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 3560,00 ISK | +1,42% | 94,8 MISK

2026-03-03 22:05:00 Oculis birtir uppgjör fyrir fjórða ársfjórðung og árið 2025 og kynnir áfanga í rekstri félagsins 3510,00 ISK | +3,54% | 96,7 MISK

2026-03-03 22:05:00 Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update 3510,00 ISK | +3,54% | 96,7 MISK

2026-02-27 22:15:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-02-18 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated 3500,00 ISK | -0,85% | 71,7 MISK

2026-02-17 10:00:00 Oculis Appoints Katie Kazem as Chief Legal Officer 3530,00 ISK | +1,73% | 291 MISK

2026-01-08 10:00:00 Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference 2790,00 ISK | +4,49% | 453 MISK

2026-01-06 10:00:00 Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis 2770,00 ISK | +10,36% | 525 MISK

2026-01-06 10:00:00 Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu 2770,00 ISK | +10,36% | 525 MISK

2026-01-06 10:00:00 Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis 2770,00 ISK | +10,36% | 525 MISK

2025-12-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2650,00 ISK | -1,49% | 5,64 MISK

2025-12-03 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2460,00 ISK | +2,50% | 69,4 MISK

2025-11-28 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2025-11-18 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2450,00 ISK | +1,24% | 13,2 MISK

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-05 10:00:00 Oculis to Participate in Upcoming November Investor Conferences 2450,00 ISK | +1,03% | 45,4 MISK

2025-10-30 09:30:44 Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-30 09:17:40 Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-30 09:17:40 Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-14 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2600,00 ISK | +0,39% | 350 MISK

2025-10-14 10:00:00 Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 2590,00 ISK | +0,19% | 19,1 MISK

2025-10-08 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2530,00 ISK | +5,42% | 611 MISK

2025-10-06 10:07:00 Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar 2190,00 ISK | +3,79% | 63,2 MISK

2025-10-06 10:07:00 Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy 2190,00 ISK | +3,79% | 63,2 MISK

2025-09-26 22:05:00 Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

2025-09-22 10:00:00 Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS 2050,00 ISK | -1,44% | 43,9 MISK

2025-09-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2090,00 ISK | +1,46% | 18,1 MISK

2025-09-04 19:00:00 Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 2080,00 ISK | +1,96% | 58,1 MISK

2025-09-03 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2040,00 ISK | +2,00% | 450 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden